Milrinone therapy for enterovirus 71-induced pulmonary edema and/or neurogenic shock in children: A randomized controlled trial

Critical Care Medicine

Volumn 41, Issue 7, 2013, Pages 1754-1760

  Chi, Chia Yu ^a,b   Khanh, Truong Huu ^c   Thoa, Le Phan Kim ^c   Tseng, Fan Chen ^a   Wang, Shih Min ^b,d   Thinh, Le Quoc ^c   Lin, Chia Chun ^a   Wu, Han Chieh ^a   Wang, Jen Ren ^b,d   Hung, Nguyen Thanh ^c   Thuong, Tang Chi ^c   Chang, Chung Ming ^a   Su, Ih Jen ^a   Liu, Ching Chuan ^b,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c Children's Hospital   (Viet Nam)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

brainstem encephalitis; enterovirus 71; milrinone; neurogenic shock; pulmonary edema

Indexed keywords

DOBUTAMINE; DOPAMINE; IMMUNOGLOBULIN; MILRINONE;

ARTICLE; ASSISTED VENTILATION; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; ENCEPHALITIS; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FEMALE; HUMAN; INFANT; LENGTH OF STAY; LOADING DRUG DOSE; LUNG EDEMA; MALE; MORTALITY; NEUROGENIC SHOCK; OPEN STUDY; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHOCK; SURVIVOR; TREATMENT DURATION;

CARDIOTONIC AGENTS; CHILD, PRESCHOOL; DOBUTAMINE; DOPAMINE; ENTEROVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULINS; INFANT; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MILRINONE; PROSPECTIVE STUDIES; PULMONARY EDEMA; RESPIRATION, ARTIFICIAL; SHOCK; VIETNAM;

EID: 84880572671     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828a2a85     Document Type: Article

References (37)

1. Chan LG, Parashar UD, Lye MS, et al: Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: Clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis; 31:678-683
2. Ho M, Chen ER, Hsu KH, et al: An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-935
3. McMinn P, Stratov I, Nagarajan L, et al: Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001; 32:236-242
4. Beig FK, Malik A, Rizvi M, et al: Etiology and clinico-epidemiological profile of acute viral encephalitis in children of western Uttar Pradesh, India. Int J Infect Dis 2010; 14:e141-e146
5. Chang LY, Huang YC, Lin TY: Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 1998; 352:367-368
6. Lin TY, Twu SJ, Ho MS, et al: Enterovirus 71 outbreaks, Taiwan: Occurrence and recognition. Emerging Infect Dis 2003; 9:291-293
7. Lum LC, Wong KT, Lam SK, et al: Fatal enterovirus 71 encephalomyelitis. J Pediatr 1998; 133:795-798
8. Nolan MA, Craig ME, Lahra MM, et al: Survival after pulmonary edema due to enterovirus 71 encephalitis. Neurology 2003; 60:1651-1656
9. Chang LY, Hsia SH, Wu CT, et al: Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J 2004; 23:327-332
10. Wang SM, Lei HY, Huang MC, et al: Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema. Pediatr Pulmonol 2005; 39:219-223
11. Pallansch M, Roos R: Enterovirus: Polioviruses, coxsackieviruses, echoviruses and newer enteroviruses. In: Fields Virology. Knipe DM, Howley PM, Griffin DE, et al (Eds). Philadelphia, Lippincott Williams & Wilkins, 2007, pp 839-893
12. Packer M, Carver JR, Rodeheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468-1475
13. Shipley JB, Tolman D, Hastillo A, et al: Milrinone: Basic and clinical pharmacology and acute and chronic management. Am J Med Sci 1996; 311:286-291
14. Dent G, Magnussen H, Rabe KF: Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994; 172:129-146
15. Gong M, Lin XZ, Lu GT, et al: Preoperative inhalation of milrinone attenuates inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass. Med Princ Pract 2012; 21:30-35
16. Jan SL, Lin SJ, Fu YC, et al: Extracorporeal life support for treatment of children with enterovirus 71 infection-related cardiopulmonary failure. Intensive Care Med 2010; 36:520-527
17. Tu PV, Thao NT, Perera D, et al: Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerging Infect Dis 2007; 13:1733-1741
18. Hsia SH, Wu CT, Chang JJ, et al: Predictors of unfavorable outcomes in enterovirus 71-related cardiopulmonary failure in children. Pediatr Infect Dis J 2005; 24:331-334
19. Gilbert GL, Dickson KE, Waters MJ, et al: Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J 1988; 7:484-488
20. Ryu WS, Kang B, Hong J, et al: Clinical and etiological characteristics of enterovirus 71-related diseases during a recent 2-year period in Korea. J Clin Microbiol 2010; 48:2490-2494
21. Deibel R, Gross LL, Collins DN: Isolation of a new enterovirus (38506). Proc Soc Exp Biol Med 1975; 148:203-207
22. Huang CC, Liu CC, Chang YC, et al: Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341:936-942
23. Kao SJ, Yang FL, Hsu YH, et al: Mechanism of fulminant pulmonary edema caused by enterovirus 71. Clin Infect Dis 2004; 38:1784-1788
24. Lin TY, Hsia SH, Huang YC, et al: Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 2003; 36:269-274
25. Wang SM, Lei HY, Huang KJ, et al: Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: Roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 2003; 188:564-570
26. Wang JN, Yao CT, Yeh CN, et al: Critical management in patients with severe enterovirus 71 infection. Pediatr Int 2006;48:250-256
27. Lin TY, Chang LY, Hsia SH, et al: The 1998 enterovirus 71 outbreak in Taiwan: Pathogenesis and management. Clin Infect Dis 2002; 34(Suppl 2):S52-S57
28. Yamani MH, Haji SA, Starling RC, et al: Comparison of dobutaminebased and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. Am Heart J 2001; 142:998-1002
29. Loughnan PM, Brown TC, Edis B, et al: Neurogenic pulmonary oedema in man: Aetiology and management with vasodilators based on haemodynamic studies. Anaesth Intensive Care 1980; 8:65-71
30. Young JB: New therapeutic choices in the management of acute congestive heart failure. Rev Cardiovasc Med 2001; 2(Suppl 2):S19-S24
31. Barton P, Garcia J, Kouatli A, et al: Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double-blinded, randomized, placebo-controlled, interventional study. Chest 1996; 109:1302-1312
32. Hayashida N, Tomoeda H, Oda T, et al: Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 1999; 68:1661-1667
33. Desmond RA, Accortt NA, Talley L, et al: Enteroviral meningitis: Natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother 2006; 50:2409-2414
34. Pevear DC, Tull TM, Seipel ME, et al: Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999; 43:2109-2115
35. Rotbart HA, Webster AD; Pleconaril Treatment Registry Group: Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001; 32:228-235
36. Bryant PA, Tingay D, Dargaville PA, et al: Neonatal coxsackie B virus infection-a treatable disease? Eur J Pediatr 2004; 163:223-228
37. Shia KS, Li WT, Chang CM, et al: Design, synthesis, and structureactivity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 2002; 45:1644-1655